Who is sponsoring NCT06167941?

NCT06167941 is sponsored by Korea University Guro Hospital.

What drugs are being tested in NCT06167941?

Interventions in NCT06167941: Lung cancer types.

What condition does NCT06167941 study?

NCT06167941 studies Expression of Integrin ανβ3 in Lung Cancer.

Is NCT06167941 still recruiting?

NCT06167941 is currently completed. Last updated 13 December 2023.

Last reviewed 2023-12-13 · How we verify

NCT06167941

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Identification of Integrin ab Expression in Lung Cancer Patients

Completed Last updated 13 December 2023

What this trial tests

trial testing Lung cancer types in Expression of Integrin ανβ3 in Lung Cancer in 61 participants. Completed in 25 November 2021.

Timeline

19 December 2019

Primary endpoint
10 September 2021

25 November 2021

Quick facts

Lead sponsor	Korea University Guro Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	61
Start date	19 December 2019
Primary completion	10 September 2021
Estimated completion	25 November 2021
Sites	1 location across South Korea

Drugs / interventions tested

Lung cancer types — full drug profile →

Conditions studied

Expression of Integrin ανβ3 in Lung Cancer — all drugs for Expression of Integrin ανβ3 in Lung Cancer →

Sponsor

Korea University Guro Hospital

Who can join

Adults 20 to 80, any sex, with Expression of Integrin ανβ3 in Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It has been reported that the expression rates of integrin αvβ3 and integrin αvβ5 in NSCLC are 89% and 100%, respectively. Among RGD (Arg-Gly-Asp) peptides, cRGDyK peptide (cRGD) known as integrin ανβ3 and ανβ5 antagonist has been widely used for targeting various cancers including NSCLC, glioblastoma, and colon carcinoma as well as prostate cancer. In this study, the investigators aim to analysis the expression of integrin ανβ3 in lung cancer patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Korea University Guro Hospital trials

Trials by the same sponsor.

NCT07009769 — AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy · completed
NCT06752733 — Cardiac Stunning After Electrical Cardioversion · active not recruiting
NCT06202690 — SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC · NA · not yet recruiting
NCT06889259 — Efficacy and Safety of CBT on Tinnitus · NA · completed
NCT05704621 — Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Mai · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06167941 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Korea University Guro Hospital
Last refreshed: 13 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06167941.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing